📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-28 23:38
330 analysed today
FollowTelegram
330
Today
150,769
All-time analysed
43,177
Positive
6,703
Negative
92,116
Neutral
8,705
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
60% Growth Guidance for FY27 and ₹47 Cr Order Book for Avience Biomedicals
Avience Biomedicals reported FY26 revenue of ₹52.51 cr, a 16% YoY increase, with PAT growing 23.31% to ₹8.75 cr. Management has provided a strong growth guidance of at least 60% for FY27, aiming to exceed ₹100 cr in revenue, backed by a current order book of ₹47 cr. A new manufacturing facility is slated to become operational in October 2026, which is expected to enable participation in larger government tenders and boost export capabilities. The company maintains a high-margin profile with EBITDA margins improving to 28.45% in FY26.
Confidence: HIGH
What changedThe company is transitioning from a trading-heavy model to increased in-house manufacturing with a significantly larger order book and a new facility nearing completion.
Why it mattersThe shift toward closed-loop systems (80-90% of reagent business) and in-house manufacturing is designed to secure recurring revenue and protect high EBITDA margins as the company scales.
FY26 Revenue: ₹52.51 crOrder Book vs FY26 Revenue: 89.5%FY27 Revenue Target: >₹100 crEBITDA Margin: 28.45%PAT Growth (YoY): 23.31%Traded Goods Revenue Share: 72.38%
📅 Short termThe stock may see positive sentiment driven by the aggressive 60% growth guidance and the substantial order book relative to its current revenue base.
📈 Long termStructural growth depends on the successful ramp-up of the new facility and the ability to win larger government tenders, potentially re-rating the company from a regional player to a national manufacturer.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependence on traded products (72.38% of turnover)
- Execution risk for the new manufacturing facility
- Regional concentration in Delhi NCR and Uttar Pradesh
Key Highlights
FY26 Revenue increased to ₹52.51 cr from ₹45.24 cr in FY25, with EBITDA margins expanding to 28.45%.
Current order book stands at approximately ₹47 cr, representing nearly 90% of FY26 total revenue.
Management targets minimum 60% revenue growth for FY27, with potential to cross the ₹100 cr mark.
New manufacturing facility completion is targeted for September 2026 with production starting in October.
Exports target set at ₹5-7 cr for the current year, with ₹70-80 lakh already achieved in the first quarter.
👀 What to Watch
Monitor the timely commissioning of the new manufacturing facility in October 2026 and the conversion of the ₹47 cr order book into revenue during H2 FY27.
Avience Biomedicals Reports FY26 Net Profit of 1,246.58 vs 976.88 YoY; Capex at 1,344.86
Avience Biomedicals reported a net profit (before tax) of 1,246.58 for the year ended March 31, 2026, up from 976.88 in the previous year. The company demonstrated improved operational efficiency with net cash from operations rising to 590.62 from 339.43 YoY. A significant capital expenditure of 1,344.86 was recorded for property, plant, and equipment, indicating aggressive expansion. As an SME-listed entity, the company remains exempt from certain corporate governance disclosures and continues to report under Indian GAAP.
Confidence: HIGH
What changedThe company has finalized its audited financial results for FY26, confirming a growth trajectory in profits and a major shift towards capital investment.
Why it mattersThe significant capex suggests the company is scaling its manufacturing capacity in the medical devices sector, though the resulting decrease in cash reserves and increase in receivables warrant attention.
Net Profit Before Tax (FY26): 1,246.58Net Profit Before Tax (FY25): 976.88Operating Cash Flow (FY26): 590.62Capex (FY26): 1,344.86Closing Cash Balance: 227.47
📅 Short termThe market is likely to view the profit growth and clean audit report favorably in the coming weeks.
📈 Long termThe structural focus on capacity expansion in medical devices could lead to significant scale-up, provided the company manages its working capital and SME-to-Mainboard transition effectively.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Tightening cash position (down ~46% YoY)
- Significant increase in trade receivables (410.41)
- SME-specific disclosure exemptions regarding related party transactions
Key Highlights
Net profit before tax grew to 1,246.58 in FY26 from 976.88 in FY25
Net cash generated from operating activities increased by 74% to 590.62
Substantial investment in property, plant, and equipment totaling 1,344.86 during the year
Cash and cash equivalents decreased to 227.47 from 421.98 due to high investing activities
Statutory auditors issued an unmodified audit opinion for the financial year
👀 What to Watch
Investors should monitor the revenue contribution from the new 1,344.86 capex in the medical devices segment and track the management of trade receivables, which saw a 410.41 increase during the year.
